AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: ULTOMIRIS (Alexion Pharmaceuticals, Inc.) (ultomiris.com)
This is a low-BS, high-substance pharmaceutical site. It prioritizes clinical evidence and mandatory safety information over marketing narratives, providing users with technical specifications rather than vague promises.
Improve the homepage H1 hierarchy to mirror the high specificity of the sub-pages. Ensure that all clinical trial results are linked directly to their ClinicalTrials.gov registry numbers for maximum transparency. Consider adding a ‘Professional’ vs ‘Patient’ toggle more prominently to separate high-density technical data from patient resources. Update the 2024 dated references on the aHUS page to maintain the ‘current’ credibility modifier for 2026.
The information density is exceptionally high for a patient-facing site. Headings like ‘People taking ULTOMIRIS had ZERO relapses during the clinical trial’ provide immediate, quantifiable outcomes rather than fluff. The body text is dominated by technical safety protocols and specific dosing schedules (e.g., ‘1,100 mg/11 mL’ in the gMG schema), resulting in a very low fluff-to-substance ratio.
When your heading hierarchy collapses, AI cannot determine where one idea ends and the next begins. Run a Semantic HTML Machine Readability Audit to see how your structure is actually chunked by LLMs.
There is virtually zero semantic drift between pages. The homepage acts as a gateway to four specific indications (NMOSD, gMG, aHUS, PNH), and the sub-pages deliver deep clinical data for exactly those conditions. The primary signal of ‘long-acting treatment’ is consistently backed by the 8-week dosing interval mentioned across all sub-pages.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
The site avoids traditional trust theatre like unverified 5-star reviews. Instead, it relies on FDA-regulated proof paths, including full Prescribing Information and the REMS program. While it uses a patient story (Kass’ story), it explicitly labels images as ‘Actor portrayal,’ which is a high-integrity signal in medical marketing.
The ratio of verifiable evidence to assertions is high. For every marketing headline about ‘freedom,’ there is a corresponding technical specification regarding infusion frequency (6-7 times per year) or clinical results. The use of a ‘Patient Safety Card’ and specific 16-week monitoring periods for PNH demonstrates high clinical accountability.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The site does carry some industry-standard clichés such as ‘enjoy her journey’ and ‘moving forward with continuous symptom control.’ However, these are anchored to unique value propositions like being the ‘1st and only long-acting C5 inhibitor.’ The template language is specific to Alexion (OneSource support program) rather than generic boilerplate.
Authority is well-established through detailed JSON-LD schema on the gMG page, which identifies the manufacturer (Alexion Pharmaceuticals) and the specific drug mechanism. There are no major authority gaps; the site clearly identifies itself as an official brand property and provides professional-grade regulatory documentation.
The performance claims are bold but strictly quantified. Claiming a ‘98.6% reduced risk of relapse’ is a massive performance assertion that is immediately qualified by placebo-controlled clinical trial data. The marketing tone is secondary to the regulatory and clinical substance.
Medical Devices, Pharma & Biotech BS: ULTOMIRIS (Alexion Pharmaceuticals, Inc.) (ultomiris.com)
The website perfectly aligns with the Pharma and Biotech industry. The high volume of mandatory Important Safety Information (ISI), Boxed Warnings, and specific clinical trial data (98.6% reduction in relapse) confirms a highly regulated medical product site.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The score of 16 is driven by the site's extreme specificity and adherence to regulatory transparency. Most points were lost in the Commodity Fingerprint pillar due to standard pharma 'patient journey' cliches, but the Information Density and Semantic Coherence pillars are nearly flawless.”